Company intelligence
NeoTargets AB
Combining AI-enabled in silico target identification with biomarker-led validation across cancers and drug modalities
About NeoTargets AB
NeoTargets is an oncology-focused biotech company developing de-risked, partner-ready cancer drug discovery programs. The company combines AI-enabled in silico target identification with biomarker-led validation across cancer models, patient samples, translational toxicity models and in vivo studies to identify safer, more selective therapeutic targets and advance de-risked preclinical drug discovery programs. NeoTargets’ modality-agnostic platform supports programs across small molecules, cyclic peptides, RNAi and bifunctional approaches, with assets designed for collaboration, licensing or sale.
Verified activity
Signals from NeoTargets AB
1 published signal